Transmedics Group, INC

TransMedics Group, Inc. issued additional information clarifying the significant impact of a $103.3 million U.S. tax valuation allowance release on its previously reported fourth-quarter 2025 financial results.

TransMedics Group, Inc. reported robust financial results for the fourth quarter and full year 2025, driven by significant revenue growth and increased adoption of its OCS NOP program.

TransMedics Group, Inc. announced significant leadership transitions, appointing new Chief Commercial Officer and General Counsel while retaining outgoing executives in new capacities.

TransMedics Group, Inc. has entered a major 16-year lease for a new 498,286 sq ft headquarters in Somerville, MA, with options to extend and purchase, signaling significant long-term strategic expansion.

TransMedics Group, Inc. announced robust third-quarter 2025 financial results, including a 32% revenue increase and raised full-year guidance, driven by strong OCS and NOP utilization.

TransMedics Group, Inc. acquired another fixed-wing aircraft for approximately $14.5 million, bringing its total fleet to 22 for its National OCS Program.

TransMedics Group reports significant revenue and net income growth for Q3 and the first nine months of 2025, driven by its OCS and NOP programs.

TransMedics Group, a medical technology company, announced significantly increased revenue and net income for the second quarter and first half of 2025, driven by robust adoption of its Organ Care System and National OCS Program, alongside plans for international manufacturing expansion.

TransMedics Group's Q1 2025 revenue surged by 48% year-over-year, driven by increased adoption of its Organ Care System (OCS) and National OCS Program (NOP).

TransMedics Group's Q3 2024 results show significant revenue growth and a shift to profitability, driven by increased adoption of their Organ Care System (OCS) and National OCS Program (NOP).

TransMedics Group's Q2 2024 results show significant revenue growth and a shift to profitability, driven by increased adoption of their Organ Care System (OCS) and expansion of their National OCS Program (NOP).

TransMedics Group's first quarter of 2024 saw a significant increase in revenue and a shift to profitability, driven by the adoption of their Organ Care System (OCS) technology.

TransMedics Group, Inc. reported significant revenue growth and net income for fiscal year 2025, driven by its OCS technology and National OCS Program, despite identifying a material weakness in internal controls.

TransMedics Group, Inc. reports significant revenue growth and achieves profitability in 2024, driven by adoption of its Organ Care System (OCS) and National OCS Program (NOP).

TransMedics Group, Inc. secures additional financial backing and expands its operational capabilities through a series of agreements and acquisitions, including the assumption of debt and the purchase of an aviation company.

Nicholas Corcoran, See remarks of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Gerardo Hernandez, Chief Financial Officer of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Waleed H Hassanein, President & CEO and a Director of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Thomas J. Gunderson, a Director at TransMedics Group, Inc., reported a transaction involving the sale of common stock.

Director Thomas J. Gunderson acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Director Edward M. Basile acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of a routine equity grant.

TransMedics Group, Inc. announces its 2026 Annual Meeting of Shareholders, detailing director elections, executive compensation, stock incentive plan amendments, and auditor ratification.

TransMedics Group, Inc. will hold its annual shareholder meeting on May 22, 2025, to vote on director elections, executive compensation, and auditor ratification.

TransMedics Group announces its 2025 Annual Meeting of Shareholders and highlights a successful 2024 marked by significant revenue growth and profitability.

TransMedics Group, Inc. announces its 2024 Annual Meeting of Shareholders to be held on May 23, 2024, outlining key proposals for voting.

TransMedics Group, Inc. has released its proxy statement detailing the agenda for its upcoming annual meeting, including the election of directors, an advisory vote on executive compensation, and ratification of the company's independent auditor.

Vanguard Capital Management has reported beneficial ownership of 5.06% of TransMedics Group Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 1,949,420 shares, representing 5.68% of TransMedics Group Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in TransMedics Group Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 14.6% in TransMedics Group, Inc., totaling 4,955,262 shares of common stock.

FMR LLC and its affiliates, along with Abigail P. Johnson, have disclosed a significant 15.0% beneficial ownership stake in TransMedics Group Inc., as detailed in their latest Schedule 13G filing.